The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase III trial of s-1 plus oxaliplatin (SOX) vs s-1 plus cisplatin (SP) combination chemotherapy for first-line treatment of advanced gastric cancer (AGC): SOPP study.
 
Min-Hee Ryu
Honoraria - Bayer; Lilly; Novartis; Roche/Genentech; Sanofi; Taiho Pharmaceutical
Consulting or Advisory Role - Bayer; Lilly; Novartis; Roche/Genentech
Research Funding - Novartis
 
Young Iee Park
No Relationships to Disclose
 
Ik-Joo Chung
No Relationships to Disclose
 
Keun-Wook Lee
Research Funding - AstraZeneca; Green Cross; MSD
 
Ho-Suk Oh
No Relationships to Disclose
 
Kyung Hee Lee
No Relationships to Disclose
 
Hye Sook Han
No Relationships to Disclose
 
Bong-Gun Seo
No Relationships to Disclose
 
Jae-Cheol Jo
No Relationships to Disclose
 
Hyo Rak Lee
No Relationships to Disclose
 
Sook Ryun Park
No Relationships to Disclose
 
Yoon-Koo Kang
Consulting or Advisory Role - Lilly/ImClone; Novartis; Ono Pharmaceutical; Roche/Genentech; Taiho Pharmaceutical
Research Funding - Bayer; Novartis; Roche/Genentech